Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger by Gaudet, Mia M. et al.
Risk factors by molecular subtypes of breast cancer across a
population-based study of women 56 years or younger
Mia M. Gaudet,
Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA
Michael F. Press,
Department of Pathology, Keck School of Medicine, University of Southern California, Los
Angeles, CA, USA
Robert W. Haile,
Department of Preventative Medicine, Keck School of Medicine, University of Southern California,
Los Angeles, CA, USA
Charles F. Lynch,
Department of Epidemiology, University of Iowa, Iowa City, IA, USA
Sally L. Glaser,
Cancer Prevention Institute of California (Formerly the Northern California Cancer Center),
Fremont, CA, USA; Department of Health Research and Policy, Stanford University, Stanford,
CA, USA
Joellen Schildkraut,
Division of Prevention Research, Department of Community and Family Medicine, The Duke
Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA
Marilie D. Gammon,
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
W. Douglas Thompson, and
Department of Applied Medical Sciences, University of Southern Maine, Portland, ME, USA
Jonine L. Bernstein
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New
York, NY, USA
Mia M. Gaudet: mia.gaudet@cancer.org
Abstract
Differences in incidence, prognosis, and treatment response suggest gene expression patterns may
discern breast cancer subtypes with unique risk factor profiles; however, previous results were
based predominantly on older women. In this study, we examined similar relationships in women
≤56 years, classified by immunohistochemical staining for estrogen receptor, progesterone
receptor, and human epidermal growth factor receptor-2 for 890 breast cancer cases and 3,432
frequency-matched population-based controls. Odds ratios (OR) and 95% confidence intervals
(CI) for tumor subtypes were calculated using multivariate polytomous regression models. A total
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of 455 (51.1%) tumors were considered luminal A, 72 (8.1%) luminal B, 117 (13.1%) non-luminal
HER-2/neu+,and 246 (27.6%) triple negative. Triple negative tumors were associated with breast
feeding duration (per 6 months: OR = 0.76, 95% CI 0.64–0.90). Among pre-menopausal women,
increasing body size was more strongly associated with luminal B (OR = 1.73, 95% CI 1.07–2.77)
and triple negative tumors (OR = 1.67, 95% CI 1.22–2.28). A history of benign breast disease was
associated only with increased risk of luminal A tumors (OR = 1.89, 95% CI 1.43–2.50). A family
history of breast cancer was a risk factor for luminal A tumors (OR = 1.93, 95% CI 1.38–2.70)
regardless of age, and triple negative tumors with higher risks for women <45 (OR = 5.02, 95% CI
2.82–8.92; P for age interaction = 0.005). We found that little-to-no breastfeeding and high BMI
were associated with increased risk of triple negative breast cancer. That some risk factors differ
by molecular subtypes suggests etiologic heterogeneity in breast carcinogenesis among young
women.
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Introduction
Human breast tumors present with diverse clinical and histopathological features. Gene
expression microarray profiles of breast cancer have demonstrated that tumors can be
classified into molecular subtypes with distinct tumor characteristics, treatment responses,
and prognosis [1-3]. Proxies of these molecular subtypes can be determined by
immunohistochemical stains of estrogen receptor-α (ER), progesterone receptor (PR), and
human epidermal growth factor receptor (HER)-2/neu proteins. Together, the three markers
are used to define four tumor subtypes: luminal A (ER+ or PR+ and HER-2/neu−), luminal
B (ER+ or PR+, HER-2/neu+), non-luminal HER-2/neu+ (ER−, PR−, HER-2/neu+), and
triple negative (ER−, PR−, and HER-2/ neu−). Data from clinical studies and tumor
registries have demonstrated that 5-year recurrence-free and overall survival were lower for
non-luminal HER-2/neu+ tumors and triple negative tumors, although most data were
collected before the widespread use of the monoclonal antibody, trastuzumab, which
interferes with the HER2/neu receptor and improves the survival of non-luminal HER-2/neu
+. No such targeted therapies currently exist for triple negative tumors [4]. These tumors are
also of concern because they have been associated with younger age, African ancestry, and
BRCA1 mutations [3, 5]; and worse prognosis [3]. Although triple negative tumors are
heterogeneous with approximately 70% exhibiting basal-like characteristics, they are
commonly referred to as a single group in the clinic and in previous studies. Previous studies
conducted predominantly among postmenopausal women show that these subtypes may also
vary with respect to risk factor profiles, such as reproductive history, use of exogenous
hormones, and body size [6-10]. Given the bimodal age distribution of breast cancer overall
and for ER/PR/HER-2/neu− defined subtypes [11], it is possible that breast cancer risk
factors may vary by molecular characteristics and age/menopausal status [12]. To examine
these relationships in younger women, we examined breast cancer risk factors by molecular




The Cancer and Steroid Hormone (CASH) Study was a multicenter, population-based, case–
control study of breast, endometrial, and ovarian cancer, which was conducted to examine
the association between oral contraceptive use and cancer risk [13]. Details have been
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previously described. In brief, between December 1980 and December 1982, newly
diagnosed breast cancer cases aged 20–56 years were ascertained through the National
Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries in eight
geographic locations [13]. For the current analyses, cases and controls were included from
four of the eight SEER sites specifically, Connecticut, Detroit, Iowa, and the San Francisco–
Oakland area of northern California. For all the cases, to ensure rapid case ascertainment
(approximately 8–10 weeks after date of diagnosis), registry personnel reviewed pathology
logbooks and other medical records of hospital and clinics at least monthly. The patients'
personal physicians were then contacted for permission to approach the breast cancer case.
Patients were first contacted by mail and then a phone call to set up an in-home interview
with trained personnel. Controls were identified through random digit dialing in the same
geographic areas as the cases and were frequency matched in five-year age groups. All
CASH Study participants completed a standardized, 50-min questionnaire that included
information on family history of female cancer, anthropometry, and reproductive, medical,
and contraceptive histories using memory aids. Women who were still having regular
menstrual cycles were considered pre-menopausal; women were considered post-
menopausal if their periods had ceased for 1 year or longer; all other women were
considered perimenopausal.
Tumor tissue
Out of the 3,517 breast cancer cases, 953 had available formalin-fixed paraffin-embedded
tumor blocks. Tumor sections were cut from the tissue blocks, and a slide stained with
hematoxylin-eosin (H + E) from each subject was reviewed by a single pathologist (M.F.P.)
to confirm both that tumor was present and that the original pathological diagnosis and
grade information were correct. Pathology/ surgical reports were reviewed for additional
information, including location and size of tumor, and extent of nodal involvement. A total
of 63 cases were excluded because the embedded tumor tissue was insufficient for staining
of ER, PR, and HER-2/neu.
Slides were also stained for ER, PR, and HER-2/neu immediately after sectioning. The
pathologist (M.F.P.) also scored all slides for extent and intensity. ER and PR statuses were
determined based on previously published immunohistochemical methods [14, 15]. The
results were scored semi-quantitatively based on the visual inspection of the estimated
percent of positively stained tumor cell nuclei (minimum of 100 tumor cells) and the
intensity of nuclear staining (−: no staining, +1: weak intensity, +2: intermediate intensity,
+3: strong intensity). Tumor samples with ≥ 1% of immunostained tumor cell nuclei were
considered as positive (ER+ or PR+). HER-2/neu was stained using an
immunohistochemical staining method, as described previously [16, 17]. Results were
assessed in a blinded fashion. Each of the cases was scored as positive or negative for each
antibody and the percentage of positive tumor cells were assessed and recorded. Tumors
were considered HER-2/neu− if there was no immunostaining or weak membrane
immunostaining (n = 701) and HER-2/ neu+ if there was moderate or strong membrane
immunostaining (n = 189).
A total of 890 breast cancer cases with evidence of invasive tumor tissue had available data
on the status of ER, PR, and HER-2/neu staining. Based on the status data of these stains,
breast tumors were classified into luminal A tumors (ER+ or PR+ and HER-2/neu−),
luminal B (ER+ or PR+, HER-2/neu+), non-luminal HER-2/neu+ (ER−, PR−, HER-2/neu+),
and triple negative (ER−, PR−, and HER-2/neu−) tumors.
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The analytic set for the current study is 890 breast cancer cases and 3,432 matched controls,
who were ascertained from the same four registries. In case–control analyses, odds ratios
(OR) and 95% confidence intervals (CI) to estimate risk for molecular subtypes of breast
cancer were calculated using a multivariate polytomous regression model, including age at
reference (defined as the age at diagnosis for cases and the age at identification for controls),
study site, menopausal status (premenopausal, perimenopausal, or postmenopausal), age at
menarche (per 2 years), parity (nulliparous, or parous), age at first birth (per 5 years),
duration of breastfeeding (per 6 months), body mass index (BMI; per World Health
Organization (WHO) categories: <18.5, 18.5–24.9, 25.0–29.9, and 30.0+ kg/m2), use of oral
contraceptives (ever/never), history of benign breast disease (yes/no), and family history of
first-degree relatives with breast cancer (yes/no). To test for differences in risk factor
associations between molecular subtypes of breast tumors, we evaluated case-only logistic
regression models, adjusted for all variables under study, with molecular subtype as the
outcome variable and the risk factors as the explanatory variables. P values for tumor
heterogeneity (pTH) were reported using luminal A tumors as the ‘control” tumor subgroup.
We also examined case–control ORs by age at diagnosis (<45 years versus ≥45 years); P
values for age interaction were calculated separately for tumor subtypes. Age 45 years was
selected to capture the young age group of the bimodal distribution of breast cancer
incidence [12], while maintaining sufficient numbers of the major subtypes in our data. We
examined the alternate cut-point of age 40 years to compare results with a recent publication
[18].
All statistical analyses were performed in STATA (version 10.0).
Results
Among the 890 breast cancer cases with available data, most cases were white and between
41 and 56 years. Most tumors were ER+ (53.3%), PR+ (50.1%), and HER-2/ neu− (78.8%).
Considered together, 455 (51.1%) tumors were considered luminal A, 72 (8.1%) luminal B,
117 (13.1%) non-luminal HER-2/neu+, and 246 (27.6%) triple negative.
There were no substantial differences among the 890 breast cancer cases with tumor tissue
retrieved, who were included in the current analyses than the 2,627 cases without tissue with
respect to age and known breast cancer risk factors (Table 1). However, cases with tumor
tissue were slightly less likely to have breastfed (P = 0.037).
Distribution patterns of established risk factors by subtypes of breast cancer and controls are
presented in Table 2. Multivariable case–control analyses stratified by molecular subtype of
the breast tumor (results reported as OR and 95% CI), as well as case-only analyses using
luminal A as the baseline “control” group (results reported as pth), were calculated to
investigate possible heterogeneity in the breast cancer risk associations with known or
suspected breast cancer risk factors (Table 3). Age at reference was significantly associated
with risk of luminal A and non-luminal HER-2/neu+ tumors; however, compared to age of
diagnosis of women with luminal A tumors, women diagnosed with luminal B (pTH = 0.003)
and triple negative tumors (pTH = <0.0001) were younger. Age at menarche was inversely
associated with breast cancer risk of luminal B and had suggestive associations for luminal
A and non-luminal HER-2/neu+ tumors, but was not associated with risk of triple negative
tumors, although the OR for triple negative tumors did not differ from that of luminal A
tumors (pTH = 0.12). Nulliparous women had a higher risk of luminal A and had suggestive
associations with luminal B and non-luminal HER-2/neu+ tumor subtypes, but was not
associated with risk of the triple negative subtype. Among parous women, older age at first
birth was also associated with a weak increase in risk of luminal A, luminal B, and non-
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luminal HER-2/neu+ tumors, although relative risk estimates were not statistically
significant for luminal B and non-luminal HER-2/neu+ tumors. The estimated relative risk
of triple negative tumors was inversely associated with duration of breast feeding (per 6
months: OR = 0.76, 95% CI 0.64–0.90), and significantly differed from the risk associated
with luminal A tumors (pTH = 0.04).
Larger body size among premenopausal women was associated with higher risk of luminal
B tumors (per WHO category: OR = 1.73, 95% CI 1.07–2.77) and risk of triple negative
tumors (per WHO category: OR = 1.67, 95% CI 1.22–2.28), although in the case-only
analysis, only the risk associated with triple negative tumors was significantly different from
that of luminal A tumors (pTH = 0.026). For ever use of oral contraceptives, there was a
suggestion of an inverse association with risk only among those with luminal A tumors (OR
= 0.81, 95% CI 0.64–1.03), although results were not statistically significant. A history of
benign breast disease was associated only with increased risk of luminal A tumors (OR =
1.89, 95% CI 1.43–2.50). Women with a positive family history of breast cancer were at a
higher risk of luminal A tumors (OR = 1.93, 95% CI 1.38–2.70) and triple negative tumors
(OR = 2.54, 95% CI 1.70–3.82).
Age-stratified results (<45 years of age (Supplemental Table 1) and ≥45 years of age
(Supplemental Table 2)) were similar for known or suspected breast cancer with factors,
with the exception of family history of breast cancer (P-values for age interaction are not
shown in the tables). Women <45 years with a family history of first-degree relatives with
breast cancer, compared to those that did not, had a fivefold higher risk of triple negative
breast cancer (OR = 5.02, 95% CI 2.82–8.92), while the association for women ≥45 years
was closer to the null (OR = 1.47, 95% CI 0.81–2.65; P for age interaction = 0.005). Since
previous analyses have also considered using an age at diagnosis cut-off point of 40 years
[18], we also performed an alternative set of stratified analyses by age 40 (data not shown)
and found similar results as those stratified by age 45 (data not shown), albeit with wider
confidence intervals due to smaller numbers, in the under-40 age groups.
Discussion
In our population-based case–control study of women 56 years or younger, we observed a
higher risk of triple negative tumors associated with shorter duration of breastfeeding, and
higher body size among premenopausal women with relative risks that differed from the risk
of luminal A tumors. Overweight or obese women were also at higher risk of luminal B
breast tumors. History of benign breast disease and family history of breast cancer were risk
factors for luminal A tumors in both women <45 and ≥45 years at diagnosis. Women with a
family history of breast cancer were also at higher risk of triple negative tumors with a five-
fold increase in risk observed among women <45 years of age at reference.
Previous studies have examined known risk factors in relation to molecular subtypes of
breast cancer using case– control study designs or cross-sectional studies of cases. Of the
five case–control studies, the Polish Breast Cancer Study (PBCS; [19]) included 804 cases
(18% triple negative; aged 20–74) and 2,502 population-based controls from a minimally
screened population of women residing in the two major cities of Poland. In the Women's
Contraceptive and Reproductive Experiences (CARE) Study [20, 21], 1,197 population-
based cases (28% triple negative; aged 35–64) and 2,015 controls were enrolled from Los
Angeles County or Detroit. Both case–control and case-only analyses were conducted in the
Carolina Breast Cancer Study (CBCS; [6]) based on a racially diverse population of 1,424
premenopausal and postmenopausal cases of invasive and in situ breast cancer (26% triple
negative of which 60% were the basal-like subtype) and 2,022 controls. Using the Seattle-
Puget Sound SEER registry in two separate studies conducted between 1983–1990 and
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1990–1992, 897 cases (20.8% triple negative) were recruited and age-matched to 1,569
controls aged 20–45, collectively referred to as the Seattle studies [18]. Two pooled case–
control studies (referred to herein as the Washington studies [9, 10]) conducted in western
Washington state recruited 1,224 ductal cases (6% triple negative) and 1,447 controls aged
55–79. The LACE/Pathway Studies [7], is a pooled case only study of 2,544 invasive breast
cancer cases (11.3% triple negative), which were enrolled 11 and 39 months post-diagnosis.
The long lag time in the LACE study likely introduced a survival bias, especially for the
women diagnosed with triple negative breast cancer who have a high risk of death and
recurrence in triple negative breast cancer in the first 2–3 years after diagnosis [22]. The
long lag time may explain the lower prevalence of triple negative disease in that study.
The CASH Study, on the other hand, recruited and interviewed cases within 6 months of
diagnosis, thus minimizing survival bias. We had a higher proportion of triple negative cases
than some other studies presumably due to rapid ascertainment and the younger age
distribution of the study population; however, our proportions are consistent with the Seattle
studies [18] and with the SEER registry [23]. The study also benefited from well-
characterized exposure information in a large, population-based series of breast cancer
cases. However, our study only included a small portion of all eligible cases and may have
biased observed findings for unmeasured risk factors. We had limited power to evaluate age
interactions, and the small proportion of African-American cases precluded evaluating
differences by race. ER, PR, and HER-2/neu was stained and scored by a single pathologist
(M.F.P.), thus eliminating inter-observer variability, which is particularly problematic for
scoring of HER-2/neu stains. More sensitive assays to detect the amplification of the HER2
gene are now advocated in the clinical and research literature, although concordance
between these methods and immunohistochemistry are strong and the proportion (21%) of
HER-2/neu− cases in our study is consistent with the literature [24]. Although the tumor
blocks used in this study were older, the slides were stained soon after they were cut, thus
limiting antigen degradation and false negative staining results [25–27]. We were, however,
limited by the lack of staining for the basal markers (e.g., CK5/6, EGFR) [28], and so we
were unable to distinguish between basal-like tumors and unclassified (normal-like tumors),
which some previous studies have suggested may have different etiologies [6, 8].
Overall, oral contraceptive use at the time of diagnosis and in the 10 years after ceasing use
has been associated with a slight increase in risk of breast cancer [29]. In the current
analysis, oral contraceptive use was not related to risk of any of the molecular subtypes of
breast cancer, which is consistent with most previous studies [6, 7, 20] nor was the effect
stronger when stratified by age. These findings are in contrast to the WISH study, which
found women ≤40 years of age who used oral contraceptives for ≥1 year were at a fourfold
higher risk of triple negative breast cancer (OR = 4.2, 95% CI 1.9–9.3), while oral
contraceptive use was not associated with risk in women >40 years of age [18].
This study adds further evidence [6, 9, 20] of a seemingly paradoxical relationship for the
risk of triple negative disease associated with parity and breastfeeding. Increased duration of
breastfeeding, but not parity and late age at first birth, was associated with lower risk of
triple negative tumors in our study and others [6, 9, 18–20]. Our findings further corroborate
the collaborative reanalysis of 47 epidemiologic studies in 30 countries [30], which showed
that the biological effects of long duration of breastfeeding are independent of the hormonal
effects of parity and age at first birth. Taken together, the epidemiologic evidence supports
biological mechanisms underlying the association with breastfeeding and triple negative
breast cancer that relate to the beneficial differentiation of the breast terminal ductal lobular
units [31, 32] or involution and re-absorption of initiated cells during breastfeeding cessation
[33], rather than enduring changes in ovarian hormone production [34]. Large studies,
including pooled analyses of existing studies, are necessary to confirm these observations
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and mechanistic studies are warranted to further understand whether the protective aspects
of lactation can be mimicked through lifestyle or pharmaceutical interventions.
Overall, overweight and obese women have been found to have a lower risk of
premenopausal breast cancer and higher risk of postmenopausal breast cancer [35, 36]. The
prevailing explanation of these disparate associations with greater body mass index are as
follows: in premenopausal women, obesity is associated with a greater number of
anovulatory cycles thus lower levels of estradiol [37]; while in postmenopausal women,
obesity is associated with aromatization of steroid precursors to estrogens thus higher levels
of estradiol [38, 39]. Other complimentary mechanisms, such as perturbations in the insulin/
insulinlike growth-axis and release of pro-inflammatory molecules (e.g., interleukins,
adipokines) [40–42], may also be at play. When cases were stratified into molecular
subtypes of breast cancer, however, the findings were less straightforward. Among
premenopausal women in this study and others [18, 19], the established inverse association
with higher BMI values was limited to lower risk of non-triple negative breast cancer;
whereas, risk of triple negative tumors is higher among obese premenopausal women. In the
CBCS, waist-to-hip ratio, a measure of the biologically active visceral fat, was associated
with higher risk of basal-like and luminal A tumors in premenopausal women [6]. Data on
BMI and risk of breast cancer subtypes in pre-menopausal women is sparse; additional data
are needed. If adiposity is confirmed to be associated with increased risk of triple negative
breast cancer in premenopausal women, then targeted interventions and screening may
improve risk profiles for women at high risk of this tumor subtype. Among postmenopausal
women, the current data [6, 10, 19] as well as our own do not support modification of the
BMI-breast cancer association by molecular subtypes.
A history of benign breast disease, a putative precursor of breast cancer, is associated with a
two-fold increase in breast cancer risk overall and a five-fold increase when atypical
hyperplasia is present [43]. We found that a history of benign breast disease increased risk
of luminal A breast cancer in both younger and older women. In the PBCS, the prevalence
of a history of benign breast disease was highest among luminal A breast cancer cases (11%)
compared to controls (6%) [19].
In our study, risks of luminal A and triple negative breast tumors were associated with a
family history of breast cancer. Particularly elevated risks of triple negative tumors were
observed among women <45 with a family history of breast cancer. These observations are
consistent with one previous study of postmenopausal women [10] and previous studies of
women with inherited BRCA1 mutations, who are more likely to be diagnosed with basal-
like tumors [44]. However, other population-based studies reported that the proportion of
cases with a family history of breast cancer was similar for all (or nearly all) breast cancer
subtypes [6–8, 18, 21]. Most studies that found similar proportions of family history of
breast cancer across molecular subtypes [6, 7, 18, 21] did not evaluate relative risk estimates
in multivariate models, so the effect of confounding by known or suspected breast cancer
risk factors is unknown. While the prevalence of BRCA1/2 mutations is low [45] and
unlikely to contribute to variability of findings across studies, it is possible that mutation
prevalence of studies vary due to differences in age ranges and geographical locations.
Unfortunately, neither this study nor the others have directly measured BRCA1/2 mutations
in their study populations. Furthermore, the confirmed common genetic variants identified
to-date explain only 1.9 and 9.6% of familial risk of ER- and ER+ breast cancer [46]. Thus,
the conflicting results across studies for family history of breast cancer could be due to
uncontrolled confounding of non-genetic risk factors or by unaccounted genetic
heterogeneity.
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This study demonstrates the importance of considering molecular subtypes of breast cancer
to identify etiological heterogeneity in this cancer diagnosed in young women. With the
exception of family history of breast cancer, our results are consistent with previous studies
of younger and older women; however, additional data are necessary to reject the hypothesis
that etiological differences may exist by age and molecular characteristics of the tumor, as
suggested by the age incidence patterns [11, 12]. Clarifying the risk factors for triple
negative breast tumors are of particular interest because they account for 15–20% of breast
cancers overall, have no targeted therapies, and are associated with poor 5-year survival [4].
We found that some risk factors had stronger associations with certain tumor subtypes than
those published for breast cancer risk overall. In particular, little-to-no breastfeeding and
high BMI were associated with increased risk of triple negative breast cancer. These results
provide additional evidence that breastfeeding and an ideal body weight may reduce a
woman's risk of breast cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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